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The cell cycle of hypothesis of neural dysfunction in chronic neurodegenerative conditions such as Alzheimer's disease (AD) offers a unified
approach to understanding both existing and novel strategies for drug development. At the present time, a ligand based approach is a pragmatic
solution for identifying new chemical leads on which to base future discovery and optimisation. We have pursued a ligand based approach on the
basis of public domain data to identify existing compounds capable of abrogating the cell cycle at the G0–G1 interface. Selected on this basis,
irrespective of the tissue under study, we identified several classes of compounds as potential chemical leads. Of these compounds, at least ten
have already been shown to be neuroprotective in animal models of acute neurodegeneration. Such compounds could form the basis of a screening
exercise after development of suitable screening tools. Progressing of chemical leads through such an approach will be more efficient if future
leads display relevant “drug-like” properties. Further, drug development in this arena should take account of the special concerns raised by
targeting an elderly population. This will involve accounting for frequent polypharmacy in the aging population, and age-related alterations in
physiology.
© 2007 Elsevier B.V. All rights reserved.Keywords: Alzheimer's disease; Cell cycle; Drug development; Neuroprotection1. Introduction
Neurodegenerative diseases represent a significant and
growing social and economic problem for the developed
world. Of these, Alzheimer's disease (AD) perhaps best
illustrates both the healthcare impact and potential for revenue
generation within this sphere. The cost of care for patients with
AD is $150 billion [1]. The current market for AD therapeutics is
$3 billion annually, predicted to grow to $7.9 billion in 2012 [1].
At present the following therapeutics are marketed for the
treatment of AD-donepezil (Aricept™), rivastigmine (Exelon™),
galantamine (Reminyl™) and memantine (Nemanda™). The first
three of these are acetylcholinesterase inhibitors, the last a
glutamate receptor antagonist. Unfortunately, these therapeutics
provide only symptomatic relief, rather than targeting underlying⁎ Corresponding author.
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doi:10.1016/j.bbadis.2006.12.004disease mechanisms, i.e., they are not disease modifying. As such,
despite current state of the art therapeutics, individuals with AD
face inevitable declines in cognition. Therefore, it is not surprising
that the impact of therapeutics targeting symptomatic relief in
patients with AD has been questioned, particularly with respect to
cost effectiveness [2], although current analysis may not have
explored potential neuroprotective effects in patients [3].
The development of potential disease modifying therapeutics
has frequently had a basis in targeting the deposition of
amyloid-β known to occur in patients with AD [4]. However, as
discussed elsewhere [5], the role played by amyloid-β in AD
remains the subject of debate. On the other hand, the cell cycle
hypothesis is a novel pathophysiological approach to neurode-
generation in AD [6–10]. This hypothesis that has the virtue of
suggesting a potential explanation for alterations in amyloid-β
processing as well as other pathological derangements of
neuronal metabolism [11]. For example, it is known that cell
cycle dependent mechanisms regulate phosphorylation and
Table 1
Desirable properties of chemical leads used in drug discovery research targeting
the cell cycle basis of Alzheimer’s disease
Property Relates to:
Abrogates cell cycle at G0–G1 stage Efficacy
Log P=2±0.7 Favours brain penetration
Log P≈2 Favours oral Absorption
Log P<4 Avoids distribution into fatty tissue
Metabolism—if hepatic polyzymic Less variable pharmacokinetics
Absence cytochrome p450 inhibition
or induction
Reduced drug–drug interaction
Lack of sedative or motor effects Side effects
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of the cell cycle hypothesis of AD is the derivation of new
potential therapeutic approaches. In this review, we focus on
issues relating to drug development around the cell cycle
hypothesis.
2. The cell cycle hypothesis
The cell cycle hypothesis proposes that either mitogenic
signalling, or cell cycle control, or both, are deranged with
respect to neurons within the brain of individuals with AD
[13,14]. Therefore pharmacological intervention targeting
mitogenic signalling or cell cycle control should act against
the neurodegeneration seen in this condition. Further, since
neurons engaged in a derangement of cell cycle function will be
metabolically and functionally compromised, pharmacological
reversal of this metabolic compromise may also provide
symptomatic relief.
Of mitogenic signals in cell cycle-mediated neurodegenera-
tion, some are well known and have been subject to drug
development research for some time. For example, excitotoxi-
city and hypoxia are suggested mitogens, as are pro-
inflammatory processes and elevations in growth factor release
[14–16]. Therefore antagonists of glutamate excitotoxicity
could be envisaged as decreasing mitogenic drive and cell
cycle activation in AD brain. According to this, the sympto-
matic relief offered by the glutamate antagonist memantine [17]
is in accord with the cell cycle hypothesis. Similarly,
acetylcholinesterase inhibitors, known to be clinically active
in AD patients, may have cell cycle-related activity, arresting
mitosis in neuroblastoma cells [18]. However, approaches such
as the excitotoxic hypothesis or theories based on inflammation
of the CNS are capable of suggesting potential therapeutic
approaches without recourse to the cell cycle hypothesis.
Therefore, it is more of interest to focus on candidate
therapeutics identified specifically by the cell cycle hypothesis
that would not be identified by other approaches.
Neurons undergo cell cycle progression in AD, to the point
that DNA replication occurs [19]. DNA replication presumably
produces a gene dosage effect and, in this regard, it is notable
that individuals with Down's Syndrome also suffer from a
trisomy 21 gene dosage effect, and that all individuals with
Down's Syndrome will develop AD-type clinical and patholo-
gical changes. Therefore, any approach tackling the metabolic
consequences of DNA replication in AD may have some
therapeutic utility. However, since drug development in this
arena awaits further research, at the present time, there are no
data available to delineate among the numerous potential targets
defined by this approach.
3. Drug development
According to the cell cycle hypothesis, neurons in AD have
left quiescence and progressed from G0 to the G1 phase of the
cell cycle. As such, a potential therapeutic approach would be to
target aborting progression through the cell cycle at this early
stage. A potential therapeutic capable of this approach wouldprevent neurons entering the S phase, and neurons treated in this
way would not suffer either a gene dosage effect or subsequent
neurodegeneration.
Attempts to trigger abrogation of the cell cycle at the G0–G1
interface can be derived from two starting points. The first
would rely on an understanding of the neuronal “cell cycle” and
its relationship to the cell cycle in dividing tissues. A complete
mapping of the neuronal cell cycle in this way would generate
targets defined by molecular biology capable of forming the
basis of drug discovery research. This level of understanding
may not yet be complete.
A second route forward centres on taking a compound based
approach, rather than focussing on molecular biological targets.
This less elegant, but potentially more pragmatic strategy,
would involve identifying compounds with a known ability to
trigger reversion through the G0–G1 “gate”, and so prevent cell
cycle progression, in other tissues. These compounds can then
become “chemical leads” For the purposes of this discussion,
“chemical leads” are defined as compounds forming a starting
point for driving forward screening of potential therapeutics,
having a desired pharmacological activity. Such compounds
form the basis for future drug development, in that manipulating
such a lead via synthetic medicinal chemistry may produce
compounds with greater efficacy or an improved safety profile.
Commonly within the pharmaceutical industry, chemical leads
are New Chemical Entities. We are suggesting here that existing
compounds may also function as chemical leads, and we have
reviewed available data accordingly. The proposal here there-
fore is to screen known compounds that in many cases are
already available in the clinic, primarily to inform development
of novel medicines. A corollary benefit of this approach may be
derived from the fact existing compounds would be screened. If
clinically available compounds are identified as active, these
may be used therapeutically as well functioning as the building
blocks of future medicines. In order for this dual utility to exist,
any such compound would not only have activity in a cell cycle
context, but would also have to meet the criteria for a
therapeutic suitable for an aged population. Compounds
identified by such an approach should have a variety of
properties in order to have maximum utility in a population
suffering from, or at risk for, AD. These are outlined in Table 1
and are discussed in further detail below.
One source of potential chemical leads is compounds that
have previously been developed as anti-proliferatives or anti-
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arrest at the G0–G1 transition. We have looked at compounds
known to have this capability, reviewing anti-tumour agents as
well as compounds acting at this point in the cell cycle in cells
not derived from tumours. Defining potential chemical leads for
screening in this way will aid development of novel therapeutics
providing that such compounds are tolerable in an AD
population. Such tolerability may not be demonstrated by
older chemotherapeutics but is apparent in more modern
molecularly targeted anti-proliferatives. An advantage of
screening existing compounds is that such compounds will
have a known clinical profile. Therefore their suitability for use
in AD patients can examined in light of both future screening in
pre-clinical models of AD and their known tolerability in
patients.
An issue with some of these compounds relates to their
intended function in oncology—namely induction of apoptosis
and therefore the destruction of tumours. Clearly, whilst
induction of cell death is an advantage for cancer patients,
such an effect is not desirable in AD. It is therefore of
importance to examine the known data on the effects of these
compounds as neuroprotectives. Since currently there are no
ongoing programmes looking for effects of such compounds in
chronic neurodegenerative processes, we have looked at in vivo
models of acute neurodegeneration as the most sophisticated
benchmark available.
Table 2 lists compounds which are known to trigger cell
cycle arrest at the G0–G1 transition. These compounds come
from a wide range of chemical and pharmacological classes, as
diverse as flavopiridol [20], retinoic acid [21] and PD098059
[22]. The effects of these compounds in relatively sophisticated
models of acute neurodegeneration, in at least ten cases, suggest
protection against acute neurodegeneration. This suggests that
anti-proliferative and anti-tumour compounds with the ability to
cause cell cycle arrest at an early stage have a broad based
neuroprotective efficacy, and that identification of chemical
leads on the basis of identification of G0–G1 arrest ability in
many tissues is a viable approach. Another point of interest isTable 2
Known drugs that arrest cell cycle progression at the G0–G1 stage-acute neuroprote
Compound Action
Retinoic acid (Vitamin A) G0–G1 cell cycle arrest and expression of G0 pro
Calcitriol (Vitamin D) G0–G1 cell cycle arrest and other cycle regulator
Flavopiridol Ras-MAPK-Apt and cyclin D1, G0–G1 cell cycle
Glucocorticoids Dexamethasone enhances vitamin D response, G
Interferon-alpha G0–G1 arrest
PD 0332991 G1 cell cycle arrest via cdk 4/6 inhibition
Inositol hexaphosphate (IP6) G0–G1 cell cycle arrest
N6-isopentenyladenosine G0–G1 cell cycle arrest via inhibiting farnesyl di
Simvastatin G0/G1 cell cycle arrest
Taurine G0/G1 cell cycle arrest
TGF-beta-1 G0–G1 cell cycle arrest via induces cdk inhibitor
Interleukin-1 G0–G1 cell cycle arrest
Farnesyltransferase inhibitors G0–G1 cell cycle arrest via Ras regulation
U0126, PD098059 G0/G1 arrest through RAS-MEK-ERK inhibition
Sphingosine and ceramide G0/G1 cell cycle arrest via Rb dephosphorylation
L-796,449, Rosiglitazone G0–G1 cell cycle arrest via PPAR gamma agonis
SJ749 G0/G1 cell cycle arrest, alpha5beta1 integrin antathat, alongside memantine and at least one acetylcholinesterase
inhibitor, several compounds having potential utility in AD
have effects on aborting the cell cycle. For example, the anti-
diabetic PPAR gamma agonist glitazones Rosiglitazone and
pioglitazone [23,24] may have utility in AD. Such compounds
cause G0–G1 cell cycle arrest [25]. Similarly, the use of statins
has been reported to impact development of AD [26], and
several statins are known to arrest the cell cycle at G0–G1
[27,28].
Further investigation of potential chemical leads should
consider the potential of the compounds under consideration for
such issues as brain penetration, suitability for chronic
administration, and optimal routes of metabolism. Brain
penetration can be estimated to some degree by computing or
measuring the variable log P, since existing information allows a
prediction of likely brain penetration based on this value. Many
chemotherapeutics and anti-proliferatives have adverse side
effects that are acceptable during acute use in oncology, but
would be unacceptable for use in prophylaxis or treatment of
AD. Finally, using a compound that is metabolised specifically
by one hepatic enzyme increases risk in development and
should be avoided.
Identification of potential chemical leads according to the
criteria above should provide tools for investigation and
screening in relevant in vitro and in vivo assay systems. Such
screening methodologies are currently being developed [29].
Once identified, compounds meeting criteria may be used in
clinical tests of the cell cycle hypothesis. Such clinical
investigation should take account of issues related to drug
development in elderly populations. Some of these issues are
discussed below.
4. Drug development in the elderly
In recent years there has been an acceptance that “adult
humans” are not a single, homogenous entity. Not only do the
sexes vary in CNS disease pathology, but differing age groups
cannot be considered equivalent. It is now widely recognisedction
Neuroprotective Reference
teins: p62 and p56 Active in rat model stroke [36–39]
y procedures Active in rat stroke model [40–42]
arrest Active in rat model of TBI [20,43]
0–G1 cell cycle arrest Active in rat model TBI [40,44,45]
ND [46]
ND [47,48]
ND [49]
phosphate synthase ND [50]
Active in rat stroke model [27,51]
Active in rat stroke model [52,53]
s cip/kip and INK4 family Active in mouse stroke model [21]
ND [54]
ND [55]
Active in TBI model [22]
Active in rat stroke model [56,57]
m Active in rat stroke model [25,58–60]
gonist ND [61]
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with regard to drug therapy. Any approach suggesting that
paediatric patients can be administered pharmaceuticals on the
basis of dose proportionality according to weight is potentially
flawed. Therefore, the FDA, for example, has for some years
sought to incentivise targeted paediatric drug development [30].
By analogy, development of potential therapeutics for popula-
tions of the age range at risk for the development of AD cannot
be entirely driven by assessments based on research on healthy
young adults. Populations over the age of sixty five differ from
younger populations in crucial ways.
The aging body will respond to medical intervention
differently from the young body. Additionally, the elderly
patient population will differ from the younger population in
terms of concomitant medication usage—Table 3 gives an
indication of the range and prevalence of concomitant
medication usage in the elderly. The elderly patient is at risk
from falls and injury associated with use of brain penetrant
medication [31], in a way not seen in younger patients. Potential
problems occur with drug interactions (DIs) and adverse drug
reactions (ADRs) in certain sub-populations unidentified
through trials. Drug interactions are a major issue for the drug
development process. This is especially true for elderly
populations due to polypharmacy (about 80% of the elderly
are on more than one medication concurrently [32,33] and
changes to pharmacokinetics (body's procedural responses) and
pharmacodynamics (affective responses) based on shifts in
disease and physiology.
Drug pharmacokinetics differ in the elderly. Pharmacoki-
netics describes four components which have differing
importance in terms of drug application and interaction:
absorption, distribution, metabolism and elimination.Table 3
Most commonly prescribed therapeutics to the elderly population
Drug Description Annual Prescriptions
(millions)
Lipitor Statin 63.2
Hydrochlorothiazide Diuretic 42.8
Atenolol Beta blocker 42.0
Furosemide Loop diuretic 34.8
Norvasc Calcium channel blocker 32.6
Synthroid Hypothyroidism 30.7
Zoloft Anti-depressant 27.0
Nexium Proton pump inhibitor 22.9
Zocor Statin 22.4
Prevacid Proton pump inhibitor 22.2
Metoprolol Tartrate Beta Blocker 22.0
Plavix Anti-platelet 18.8
Fosamax Biphosphonate 17.9
Protonix Proton pump inhibitor 16.4
Toprol XL Beta blocker 16.4
Klor-Con Electrolyte replenisher 11.4
Celebrex NSAID 11.0
Actonel Biphosphonate 9.7
Prilosec Proton pump inhibitor 7.4
Xalatan Prostaglandin 6.9
Aricept Aceytlcholinesterase inhibitor 4.3
Lanoxin Digoxin 3.5Diseases and ageing can compromise gastro-intestinal
absorption. The loop diuretic furosemide, for example, has
much lower efficacy due to poor absorption in elderly patients
who have suffered from heart failure [34,35]. Drug–drug
interactions (for example between certain drugs and some
antacids) can also prevent successful absorption.
Distribution problems can occur in the elderly due to the
tendency for lower total body water, lower muscle mass and
increased body fat relative to normal adults, leaving serum
concentrations less predictable as a result of irregular volumes
of distribution. Interactions in distribution can occur due to
competitive binding for transport. For example, NSAIDS have a
tendency to displace other drug molecules from protein binding
[32].
Drug metabolism depends upon a family of hepatic enzymes:
the cytochrome p450s. Some drugs are known to induce or
inhibit some of these enzymes, either ones involved in their own
biotransformation or not, particularly in drugs with long half-
lives. In cases of polypharmacy (especially in the elderly) this
leads to unpredictable volumes of distribution and potential
dosage problems. Care must therefore be taken in prescription
so that ADRs and dangerous drug interactions do not occur.
Some drugs are excreted through renal elimination. Inter-
ference with renal excretion may therefore result in toxic levels
of drugs. Interactions can occur when urinary pH is altered by
administering ascorbic acid (or other acidifying drugs) or
antacids (or other alkalizing drugs). Other interactions can occur
in the kidneys through competition in the active transport
mechanisms of the kidneys. Examples include probenecid co-
administered with antibiotics and quinidine in conjunction with
digoxin [32].
Using the appropriate in vitro assays while carrying out pre-
clinical trials helps the drug development process. Testing for
CYP induction and inhibition, metabolic stability, plasma
protein binding, drug–drug interactions, etc. could provide
essential safety information ahead of clinical trials. It is
important that this information is treated with care though,
and not used to extrapolate blindly into human application in
phase I trials.
Pharmacodynamics of the elderly also poses a problem to
drug development. Changes to receptor affinity, post-receptor
events and homeostatic control occur in ageing. Studies of
specific volatile pharmacodynamics in the elderly have been
done with benzodiazepines and verapamil. Toxicity in some
cases may be as a result of pharmacodynamic changes.
Interactions can transpire due to these changes, due to tissue
responses and receptor binding, etc. Not much is known about
which changes occur and where, but it will depend on the
individual and is part of the ageing process, which must be
considered in drug development.
Other issues in drug development are more general. One
such issue is that elderly people need to be used in clinical trials.
Sometimes in the past, clinical trials have neglected the elderly
due to access, concerns about polypharmacy and adverse
reactions, but at least a subset of elderly participants should be
used in every trial of a medication that will be used by the
geriatric population. This would at least clarify where each new
507J. Woods et al. / Biochimica et Biophysica Acta 1772 (2007) 503–508drug has adverse effects and may even allow information to be
extracted about its interactions as well as seeing where it would
fit in with dosing regimens. At the moment, if elderly patients
are used in clinical trials, it tends to be the “young” elderly and
thus caution should be taken in translating this to older patients
where the treatments are most likely to be required.
Drug formulation can also be an issue. Due to the physical
and cognitive challenges of the elderly, the doses, containers,
pills, etc. may not be appropriate and setbacks occur. So long as
patients are monitored, dosages and other problems can be
adjusted, but it is important to be aware of these issues.
5. Conclusions
The cell cycle hypothesis of AD has generated new ideas,
and questions the utility of targeting amyloid-β deposition from
a therapeutic point of view, in distinction to addressing the
cause of altered amyloid-β processing in this disease. At the
same time, the hypothesis generates exciting new possibilities
for development of novel therapeutics.
Our current understanding of processes underlying the
neuronal “cell cycle” is potentially not sufficiently advanced to
create molecular biological targets for the development of novel
therapeutics. However, a pragmatic ligand centered pharmaco-
logical approach already suggest that identifying existing
compounds capable of arresting abnormal entry into the cell
cycle will yield new neuroprotective agents. Thus far, data have
been generated in animal models of acute neurodegeneration.
Alongside these data, compounds known to have potential
clinical utility in AD can also be shown to mediate exit from the
cell cycle. There is therefore precedent supporting drug
discovery efforts based on such an approach. Such discovery
will rely on the development of relevant screening tools.
Using such a process to identify chemical leads will be
enhanced if such chemical leads have suitable properties for use
in the clinic. That is, optimisation of chemical leads tends to
compromise general “drug like” properties of molecules, and
therefore an ideal chemical lead will present an acceptable
profile at the outset. Early consideration of potential for brain
penetration, avoidance of metabolic interactions and side effects
or toxicity on chronic administration is required, alongside
recognition of the special problems of drug development in
elderly populations.
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